In vitro cytoprotective effect of infant milk formula fortified with human rotavirus-specific hyperimmune yolk immunoglobulins (IgY)

Food Science and Biotechnology

Volumn 22, Issue 6, 2013, Pages 1699-1705

  Rahman, Shofiqur ^a   Umeda, Kouji ^a   Icatlo Jr , Faustino C ^a   Lee, Ki Woong ^b   Kim, Sung Han ^b   Choi, Hyuk Joon ^c   Han, Bok Kyung ^c   Park, Young Seo ^d   Van Sa, Nguyen ^a  

^a Immunol Research Institute in Gifu   (Japan)

^b Namyang Dairy   (South Korea)

^c BK Bio Co Ltd   (South Korea)

^d Gachon University   (South Korea)

Author keywords

immunoglobulin Y; infant formula; rotavirus

Indexed keywords

DAIRIES;

CELL DAMAGE; CLINICAL STRAINS; CYTOPROTECTIVE EFFECTS; DOSE-DEPENDENT MANNER; IMMUNOGLOBULIN Y; INFANT FORMULA; MIXED SOLUTION; ROTAVIRUSES;

VIRUSES;

EID: 84890962742     PISSN: 12267708     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10068-013-0269-4     Document Type: Article

References (25)

1. Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm. Rep. 58: 1-25 (2009).
2. Dennehy P. Rotavirus vaccines: An overview. Clin. Microbiol. Rev. 21: 198-208 (2008).
3. Ramachandran M, Das BK, Vij A, Kumar R, Bhambal SS, Kesari N, Rawat H, Bahl L, Thakur S, Woods PA, Glass RI, Bhan MK, Gentsch JR. Unusual diversity of human rotavirus G and P genotypes in India. J. Clin. Microbiol. 34: 436-439 (1996).
4. Yolken RH, Peterson JA, Vonderfecht SL, Fouts ET, Midthun K, Newburg DS. Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis. J. Clin. Invest. 90: 1984-1991 (1992).
5. Sarker SA, Pant N, Juneja LR, Hammarstrom L. Successful treatment of rotavirus-induced diarrhoea in suckling mice with egg yolk immunoglobulin. J. Health Popul. Nutr. 4: 465-468 (2007).
6. Ibrahimel SM, Rahman AK, Isoda R, Umeda K, van Sa N, Kodama Y. In-vitro and in-vivo effectiveness of egg yolk antibody against Candida albicans (anti-CA IgY). Vaccine 26: 2073-2080 (2008).
7. Nguyen SV, Icatlo FC Jr, Nakano T, Isogai E, Hirose K, Mizugai H, Kobayashi-Sakamoto M, Isogai H, Chiba I. Anti-cell-associated glucosyltransferase immunoglobulin Y suppression of salivary mutans streptococci in healthy young adults. J. Am. Dent. Assoc. 142: 943-949 (2011).
8. Sa NV, Umeda K, Yokoyama H, Tohya Y, Kodama Y. Passive protection of dogs against clinical disease due to canine parvovirus-2 by specinfant formulaic antibody from chicken egg yolk. Can. J. Vet. Res. 70: 62-64 (2006).
9. Carlander D, Kollberg H, Wejaker PE, Larsson A. Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections. Immunol. Res. 21: 1-6 (2000).
10. Ikemori Y, Kuroki M, Peralta RC, Yokoyama H, Kodama Y. Protection of neonatal calves against fatal enteric colibacillosis by administration of egg yolk powder from hens immunized with K99-piliated enterotoxigenic Escherichia coli. Am. J. Vet. Res. 53: 2005-2008 (1992).
11. Kuroki M, Ohta MY, Ikemori Y, Icatlo Jr FC, Kobayashi C, Yokoyama H, Kodama Y. Field evaluation of chicken egg yolk immunoglobulins specinfant formulaic for bovine rotavirus in neonatal calves. Arch. Virol. 142: 843-851 (1997).
12. Yokoyama H, Hashi T, Umeda K, Icatlo FC Jr, Kuroki M, Ikemori Y, Kodama Y. Effect of oral egg antibody in experimental F18+ Escherichia coli infection in weaned pigs. J. Vet. Med. Sci. 59: 917-921 (1997).
13. Hiraga C, Kodama Y, Sugiyama T, Ichikawa Y. Prevention of human rotavirus infection with chicken egg yolk immunoglobulins containing rotavirus antibody in cat. Kansenshogaku Zasshi 64: 118-123 (1990).
14. Rahman S, Higo-Moriguchi K, Htun KW, Taniguchi K, Icatlo FC Jr, Tsuji T, Kodama Y, van Nguyen S, Umeda K, Oo HN, Myint YY, Htut T, Myint SS, Thura K, Thu HM, Fatmawati NN, Oguma K. Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients. Vaccine 30: 4661-4669 (2012).
15. Ward RL. Human rotaviruses, vaccines and method. U. S. Patent 5, 474, 773 (1995).
16. Rahman AKMS, Ibrahim ESM, Isoda R, Umeda K, Nguyen VS, Kodama Y. Effect of passive immunization by anti-gingipain IgY on periodontal health of dogs. Vet. Sci. Dev. 1e-8: 35-39 (2011).
17. Moriguchi KH, Akahori Y, Iba Y, Kurosawa Y, Taniguchi K. Isolation of human monoclonal antibodies that neutralize human rotavirus. J. Virol. 78: 3325-3332 (2004).
18. Taniguchi K, Urasawa S, Urasawa T. Preparation and characterization of neutralizing monoclonal antibodies with different reactivity patterns to human rotaviruses. J. Gen. Virol. 6: 1045-1053 (1985).
19. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/ genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol. 15: 29-56 (2005).
20. Moe K, Thu HM, Oo WM, Ave KM, Shwe TT, Mar W, Kirkwood CD. Genotyping of rotavirus isolates collected from children less than 5 years of age admitted for diarrhea at the Yangon Children's Hospital, Myanmar. Vaccine 27(Suppl. 5): F89-F92 (2009).
21. Widdowson MA, Steele D, Vojdani J, Wecker J, Parashar U. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines. J. Infect. Dis. 200 (Suppl. 1): S1-S8 (2009).
22. Meiji SA, Tin SA, Khin YO, Ne W, Ghosh S, Yamamoto D, Kobayashi N. Phylogenetic analysis of human rotavirus in Myanmar: Detection of Indian-Bangladesh G1/G2 lineages, Chinese G3 lineages and OP354-like P[8] lineage (P[8]b subtype). Se. Asian J. Trop. Med. 41: 1393-1404 (2010).
23. Matthijnssens J, Ciarlet M, McDonald SM, Attoui H, Bányai K, Brister JR. Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch. Virol. 156: 1397-1413 (2011).
24. Ward RL, Nakagomi O, Knowlton DR, McNeal MM, Nakagomi T, Clemens JD, Sack DA, Schiff GM. Evidence for natural reassortants of human rotaviruses belonging to different genogroups. J. Virol. 64: 3219-25 (1990).
25. Nilsson E, Kollberg H, Johannesson M, Wejåker PE, Carlander D, Larsson A. More than 10 years' continuous oral treatment with specinfant formulaic immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: A case report. J. Med. Food 10: 375-378 (2007).